$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of the effectiveness of baricitinib/alemin tablets in the treatment of vitiligo
2026-02-01 22:25:32
Check Details
Tucatinib/Tucatinib is a targeted drug or chemotherapy drug
2026-02-01 22:25:32
Check Details
Alpelisib plus fulvestrant meets primary PFS endpoint in CDK4/6 inhibitor-pretreated patients with PIK3CA mutant HR+/HER2 breast cancer
2026-02-01 22:25:32
Check Details
Which is better, fostatinib/fotantinib or eltrombopag?
2026-02-01 22:25:32
Check Details
Treatment and relief methods for side effects of Serputinib/Serpatinib (Ruitu)
2026-02-01 22:25:32
Check Details
FDA grants accelerated approval to Voyxact (sibprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy
2026-02-01 22:25:32
Check Details
KEYNOTE-775 confirms broad efficacy of lenvatinib plus pembrolizumab in advanced endometrial cancer
2026-02-01 22:25:32
Check Details
Is Belumosudil tablets currently on the market? What is the sales situation?
2026-02-01 22:25:32
Check Details
A comprehensive analysis of the precautions for using Brivaracetam
2026-02-01 22:25:32
Check Details
What is the relevant marketing information about fezolinetant?
2026-02-01 22:25:32
Check Details
What are the indications for Obeticholic acid?
2026-02-01 22:25:32
Check Details
What are the possible adverse reactions of Obeticholic acid?
2026-02-01 22:25:32
Check Details
1
2
...
2326
2327
2328
2329
2330
2331
2332
...
2441
2442
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Hovilpri (Pritelivir) Oral Anti-HSV: Immunocompromised Adults With Acyclovir-Refractory Mucocutaneous Lesions, 63% Healing at 28 Days
2
Juvmo (tavapadon) for Adult Parkinson’s: D1/D5 Partial Agonist, Once Daily, Monotherapy or Adjunct to Levodopa
3
Emcitate (tiratricol) for MCT8 Deficiency Peripheral Thyrotoxicosis: Bypass MCT8, Lower T3, Monitor Heart Rate and Bone
4
Lyrfigtu (lirafugratinib) for Pretreated FGFR2 Cholangiocarcinoma: 70mg Daily, REFOCUS Efficacy, Ocular and Phosphate Monitoring
5
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
6
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS
7
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
8
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
9
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
10
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
11
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy
12
Zanvastro (zilganersen-alexander) Intrathecal Injection: First Targeted Therapy for Alexander Disease